Entera Bio Ltd. — Director's Dealing 2025

Jul 18, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Entera Bio Ltd. (ENTX)
CIK: 0001638097
Period of Report: 2025-07-16

Reporting Person: Burshtein Gregory (Chief of R&D)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-07-16	Ordinary Shares, par value NIS 0.0000769 per share	A	26316	—	Acquired	101442	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-07-16	Stock Option (right to buy)	$2.28	A	200000	Acquired	2035-04-28	Ordinary Shares, par value NIS 0.0000769 per share (200000)	Direct

Footnotes

F1: Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. This grant was awarded to the Reporting Person in lieu of the Reporting Person's 2024 annual cash bonus. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 28, 2025.

F2: This grant of options was approved by the Board on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. The options vest over a three-year period that commenced on April 28, 2025, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.